Science News
from research organizations

Earlier treatment for young patients with chronic hepatitis B more effective in clearing virus

Date:
September 6, 2012
Source:
Agency for Science, Technology and Research (A*STAR), Singapore
Summary:
Scientists have discovered for the first time that children and young patients with chronic hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.
Share:
         
Total shares:  
FULL STORY

Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London, discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.

This discovery by the team of scientists led by Professor Antonio Bertoletti, programme director and research director of the infection and immunity programme at SICS, could lead to a paradigm shift in the current treatment of patients with chronic HBV. The findings were published Sept. 1 in Gastroenterology.

Current guidelines from international liver associations recommend delaying therapy until HBV carriers show clear signs of active liver disease, which generally appear after the age of 30. This is based on two assumptions. One, young patients are unable to react to treatment because they are immune-tolerant to the virus. This means that there is no protective immune response in their body to help them get rid of the virus, and therefore, they will not run the risk of liver damage or inflammation. Two, HBV infection is largely harmless in HBV carriers until active liver disease is apparent.

However, Professor Bertoletti and his team showed that young patients are not immune tolerant as they posses HBV-specific T cells with the ability to produce distinct antiviral cytokines that help the body fight against HBV. They also showed that the longer a patient is left untreated, the less effective their immune system becomes against HBV and the less able the patient will be able to clear the virus from their body even when they receive treatment.

The scientists demonstrated that the presence of HBV in the body over a long period of time is harmful to the patient due to repeated activation of T-cells which induces a progressive state of T-cell exhaustion, a state of immune system dysfunction that prevents optimal control of the infection and clearance of the virus from the body. Thus, young patients produce an immune response against HBV which is less compromised than that in older patients.

Professor Bertoletti said, "Young patients infected with HBV are most at risk of developing chronic HBV but current guidelines mean that they are also the least likely to be treated. However, our findings suggest that it might be better to start treatment early as young people with their stronger immune system, respond better to treatment and are more able to clear the virus."

Prof Judith Swain, Executive Director of SICS, said, "These findings may change the way treatment is applied to patients with HBV in hospitals in Singapore and throughout the world. This is a fine example of how clinicians, physician scientists, and scientists work together to improve healthcare for the public."

Background on HBV

HBV infection affects 400 million people worldwide, 75% of whom reside in Asia. In Singapore, one in every 35 adult is a Hepatitis B carrier. Hepatitis B is the most common infection of the liver that is spread by direct contact with the blood or body fluids of an infected person. Not all HBV carriers display symptoms but lifelong infection carries the risk of serious health complications including cirrhosis, hepatocellular carcinoma, and liver failure.


Story Source:

The above story is based on materials provided by Agency for Science, Technology and Research (A*STAR), Singapore. Note: Materials may be edited for content and length.


Journal Reference:

  1. Patrick T.F. Kennedy, Elena Sandalova, Juandy Jo, Upkar Gill, Ines Ushiro–Lumb, Anthony T. Tan, Sandhia Naik, Graham R. Foster, Antonio Bertoletti. Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. Gastroenterology, 2012; 143 (3): 637 DOI: 10.1053/j.gastro.2012.06.009

Cite This Page:

Agency for Science, Technology and Research (A*STAR), Singapore. "Earlier treatment for young patients with chronic hepatitis B more effective in clearing virus." ScienceDaily. ScienceDaily, 6 September 2012. <www.sciencedaily.com/releases/2012/09/120906112257.htm>.
Agency for Science, Technology and Research (A*STAR), Singapore. (2012, September 6). Earlier treatment for young patients with chronic hepatitis B more effective in clearing virus. ScienceDaily. Retrieved April 25, 2015 from www.sciencedaily.com/releases/2012/09/120906112257.htm
Agency for Science, Technology and Research (A*STAR), Singapore. "Earlier treatment for young patients with chronic hepatitis B more effective in clearing virus." ScienceDaily. www.sciencedaily.com/releases/2012/09/120906112257.htm (accessed April 25, 2015).

Share This Page:


Health & Medicine News
April 25, 2015

Latest Headlines
updated 12:56 pm ET